NovaBridge Biosciences
HealthcareNASDAQ:NBP · NASDAQ Global Market
+$0.02 today
Vol 0.36M · Avg 0.93M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.0%
avg -133.6%
ROIC
-40.2%
avg -59.2%
ROA
-17.8%
avg -97.1%
Analysis
ROA is currently the strongest return metric at -17.8% versus its period average of -97.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Cong Xu | Senior VP and Head of R&D Center of Excellence | — | — | 41 | $290,154.00 | 0.58% |
Phillip Dennis | Chief Medical Officer | — | — | 63 | $142,740.00 | 0.28% |
Xi-Yong Fu | Chief Executive Officer & Director | — | — | 54 | $59,823.00 | 0.12% |
Mark Hagler | President & Chief Commercial Officer | — | — | — | $230,000.00 | 0.46% |
Ming Lei | Chief Financial Officer | — | — | 29 | $0.00 | <0.01% |
Sean Wuxiong Cao | Chief Business Development Officer & Director | — | — | 59 | $35,073.00 | 0.07% |
Tyler Ehler | Senior Director of Investor Relations | — | — | — | — | — |
Wei Fu | Executive Chairman | — | — | 43 | $59,823.00 | 0.12% |
Liwei Lin | General Counsel & Board Secretary | — | — | 38 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$577,300.00
Sells
2
$56,350.37
Net Sentiment
+$520,949.63
Net buying
Most Active
Xu Cong Claire
1 transactions
Analysis
Insiders reported 1 buys worth $577,300.00 and 2 sells worth $56,350.37 over the last 12 months. That adds up to net buying of $520,949.63. Xu Cong Claire was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +17.8% | +19.5% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.8% over three years. Forward estimates point to Revenue at +19.5% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages NBP?
NovaBridge Biosciences (NBP) lists 9 active executives. The top listed executive is Cong Xu, Senior VP and Head of R&D Center of Excellence.
Are NBP insiders buying or selling?
Recent insider activity shows net buying of $520,949.63.
Explore More
Continue the stock analysis
Jump to another research area for this company.